The core of the issue lies in the distinction between low drug prices and actual payability. Data from a 2024 IQVIA report reveals that patients abandoned 98 million prescriptions at U.S. pharmacies, a trend that accelerates as upfront costs climb. Research from Buzz Health indicates that pharmacy fill rates drop by 37 percentage points when out-of-pocket costs rise from $15 to $35. Paytient’s expansion seeks to bridge this gap by embedding GoodRx and Mark Cuban Cost Plus Drug Company directly into its payment ecosystem, allowing employees to manage copays that would otherwise force them to walk away from necessary treatment.

This shift mirrors the federally mandated Medicare Prescription Payment Plan introduced in 2025, which protects seniors from sudden financial burdens. Paytient is now extending similar capabilities to the private sector. According to the company's 2026 Employee Healthcare Affordability Report, 56% of members using cost-smoothing payment plans successfully adhered to their treatment regimens. This is a significant improvement, as medication nonadherence currently costs the industry approximately $100 billion annually. By partnering with major insurers such as Anthem, Optum, and Cigna, Paytient provides a mechanism for employees to spread out costs for specialty treatments—like GLP-1 medications—ensuring that financial barriers do not result in skipped doses or avoidable hospital admissions.